Get the Stockscreener App
5.65
2.25%
-0.13
Acrivon Therapeutics Inc stock is traded at $5.65, with a volume of 24,516.
It is down -2.25% in the last 24 hours and down -15.80% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$5.78
Open:
$5.8
24h Volume:
24,516
Relative Volume:
0.48
Market Cap:
$175.92M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-2.0324
EPS:
-2.78
Net Cash Flow:
$-55.26M
1W Performance:
+1.62%
1M Performance:
-15.80%
6M Performance:
-22.92%
1Y Performance:
+29.89%
1-Day Range:
$5.65
$5.88
1-Week Range:
$5.36
$6.00
52-Week Range:
$3.19
$11.90
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
5.65 | 175.92M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Barclays PLC Raises Stock Holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 6.3% in December - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
(ACRV) On The My Stocks Page - Stock Traders Daily
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Increases By 6.3% - MarketBeat
Geode Capital Management LLC Has $2.12 Million Stake in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
(ACRV) Investment Report - Stock Traders Daily
Barclays PLC Acquires 11,273 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
State Street Corp Acquires 47,233 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Consensus PT from Brokerages - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Charles Schwab Investment Management Inc. Sells 27,705 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
(ACRV) Long Term Investment Analysis - Stock Traders Daily
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha
Acrivon Therapeutics' SWOT analysis: oncology biotech stock's platform potential By Investing.com - Investing.com Nigeria
Acrivon Therapeutics' SWOT analysis: oncology biotech stock's platform potential - Investing.com India
(ACRV) Technical Data - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
HC Wainwright Issues Pessimistic Outlook for ACRV Earnings - MarketBeat
We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate - Simply Wall St
Acrivon Therapeutics’ (ACRV) “Buy” Rating Reiterated at HC Wainwright - Defense World
BMO Capital Markets Cuts Acrivon Therapeutics (NASDAQ:ACRV) Price Target to $27.00 - Defense World
When (ACRV) Moves Investors should Listen - Stock Traders Daily
Acrivon Therapeutics Reports Promising Clinical Progress and Financial Results - TipRanks
Acrivon stock retains Outperform as BMO cuts target due to minor cash adjustments - Investing.com
Acrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $27.00 by Analysts at BMO Capital Markets - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Given Buy Rating at HC Wainwright - MarketBeat
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Acrivon's Cancer Drug Shows 62.5% Response Rate; Reports $202.8M Cash Position | ACRV Stock News - StockTitan
Acrivon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.83 Average PT from Analysts - Defense World
Trend Tracker for (ACRV) - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles - Investing.com Canada
Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles By Investing.com - Investing.com South Africa
(ACRV) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Promising Endometrial Cancer Trial Data Puts Acrivon In Focus - RTTNews
Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific ConferencesHuman Proteome Organization World Congress and EORTC-NCI-AACR Symposiu - GlobeNewswire
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest - MarketBeat
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
(ACRV) Investment Analysis and Advice - Stock Traders Daily
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Yahoo Finance
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Acrivon commences Phase 1 trial for cancer drug ACR-2316 - Investing.com
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - GlobeNewswire
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):